There has been debate about the impact of enrollment on clinical trials and survival outcomes for children with cancer. Retrospective studies found that patients enrolled on clinical trials have better outcomes compared with patients not enrolled on clinical trials ([@bib9]; [@bib11]). However, a systematic review determined that these studies were limited because of confounding and selection bias, and thus concluded that the impact of trial enrollment is not clear ([@bib6]). Further, a Cochrane review found that, in general, outcomes are similar between those who do and those who do not participate in randomised trials ([@bib10]).

We recently used the Cancer in Young People in Canada (CYP-C) database, a national paediatric cancer population-based data source, to describe the proportion of all children with cancer enrolled on a clinical trial and to describe factors associated with enrollment. About one in four children with cancer were enrolled on a clinical trial ([@bib7]). The most common reasons cited for non-enrollment were lack of an available trial and physician choice. Acute lymphoblastic leukaemic (ALL) is the most common paediatric cancer, accounting for approximately one-third of all cancers in children aged 0--14 years of age. We found that children with ALL had the highest rates of enrollment among paediatric cancer diagnoses ([@bib7]).

Given this data, we next wanted to determine if enrollment on a clinical trial is associated with better survival for children with ALL. Therefore, the objectives of this analysis were to describe the impact of trial enrollment at diagnosis on event-free survival (EFS) and overall survival (OS) in paediatric ALL.

Materials and methods
=====================

Population of interest and sampling methods
-------------------------------------------

We included children with newly diagnosed ALL with ICD-O M codes 9835, 9836 and 9837; these codes define patients with precursor lymphoblastic leukaemic NOS, B-cell and T-cell, respectively. Other inclusion criteria were 1--14 years of age, diagnosed between 01 January 2001 and 31 December 2012, and treated at one of the 17 paediatric oncology centres in Canada. We excluded patients in whom enrollment status was unknown, those diagnosed \<1 year of age (infant ALL) and those with Burkitt's leukaemic. We chose to exclude infant and Burkitt's ALL as the treatment approach is fundamentally different compared with precursor lymphoblastic leukaemic.

Data source
-----------

We used the data from CYP-C, a population-based registry that aims to include all paediatric patients with cancer diagnosed between 0 and 14 years of age since 2001, who were diagnosed and treated at one of the 17 tertiary paediatric oncology centres in Canada. Two data collection approaches are used for CYP-C data. For the 5 centres in Ontario, the data are transferred to CYP-C from the Paediatric Oncology Group of Ontario (POGO) Networked Information System (POGONIS), which is a provincial population-based registry that includes similar data to CYP-C. For the 12 centres outside of Ontario, the data are entered directly into CYP-C. Elements captured by both databases include the following: (1) demographic variables, including sex, date of birth, postal code and race; (2) diagnostic details; (3) times to diagnosis and treatment; (4) treatment plan details, including enrollment on a therapeutic trial and whether the initial treatment plan was terminated early or completed as planned; and (5) outcomes such as relapse, second malignancy and death.

The reasons for non-enrollment have been consistently collected by CYP-C throughout the study period, whereas a standardised list has only recently been incorporated into POGONIS. Thus, description of reasons for non-enrollment was restricted to the 12 non-Ontario sites.

The CYP-C program achieves high-quality data through multiple approaches. A community of practice composed of each site's data manager was established to maximise the data quality through monthly teleconference and annual face-to-face training combined with site audits. The data were provided for the purpose of this analysis on 19 September 2016.

Statistical plan
----------------

Event-free survival was defined as time from diagnosis to relapse or death from any cause, whichever occurred first. Those without an event were censored on the date of last follow-up. Overall survival was defined as time from diagnosis to death from any cause or date of last follow-up. Survival was described for those enrolled and not enrolled on a therapeutic trial at diagnosis using the Kaplan--Meier method and compared using the log rank test.

In order to evaluate potential confounders, Cox proportional hazards models were created. The following variables were examined: (1) demographic features: age at diagnosis (1--4, 5--9 and 10--14), sex, race, and diagnostic era (\<2007 *vs* ⩾2007, the approximate mid-point); (2) Leukaemia features: initial white blood cell count (WBC) (⩾50 *vs* \<50 × 10^9^ l^−1^), central nervous system (CNS) status 1 (no blasts), 2 (presence \<5 *μ*l^−1^ WBCs and cytospin positive for blasts) or 3 (CSF \>5 *μ*l^−1^ WBCs and cytospin positive for blasts), immunophenotype (B-precursor *vs* T), and cytogenetic risk group; and (3) Socioeconomic factors: kilometers to the nearest tertiary care paediatric centre and neighborhood income quintile. We also stratified analyses by National Cancer Institute (NCI) standard (age \<10 years and initial WBC \<50 × 10^9 ^l^−1^) and high (age ⩾10 years or initial WBC ⩾50 × 10^9^ l^−1^) risk groups. Favourable cytogenetics were defined as trisomies 4 and 10 and *t*(12;21). Unfavourable cytogenetics were defined as hypodiploidy (\<45 chromosomes), *t*(9;22), MLL (11q23) rearrangements, and RUNX1 (AML1) amplification.

We used postal codes at diagnosis to determine distance to the nearest tertiary care paediatric cancer centre and area-level socioeconomic status by linking to the census data. Full 6 digit postal codes were available for all provinces except for British Columbia, in which 3 digit postal codes were available. Using the Statistics Canada Postal Code Conversion File software (PCCF+, Version 4J), we linked the postal code to a 2001 census dissemination area. Dissemination areas are the smallest area unit defined by Statistics Canada and include between 400 and 700 persons. Using the 2001 census, we determined income quintiles that adjust for household size and regional differences ([@bib3]).

Adjusted associations between enrollment on trials and survival outcomes were described using hazard ratios (HR) with 95% confidence intervals (CIs). Models adjusted for all demographic, leukaemic and socioeconomic factors separately and then together. Statistical significance was defined as *P*-value\<0.05. Statistical analysis was conducted using the SAS statistical program (SAS-PC, version 9.4; SAS Institute Inc, Cary, NC, USA).

Results
=======

There were 2732 identified children with ALL in CYP-C, among whom 72 had unknown enrollment status, 76 were infants\<1 year of age and 15 had Burkitt's leukaemic, leaving 2569 patients available for analysis. Of the 2569 included patients, 1408 (54.8%) were enrolled on a clinical trial at diagnosis. For the 1408 enrolled on a clinical trial, 562 (39.9%) were enrolled on Children's Oncology Group protocols, 336 (23.9%) were enrolled on Dana Farber Cancer Institute ALL Consortium protocols and the remainder were others or unknown. Conversely, for the 1161 not enrolled on a trial, 506 (43.6%) were treated according to Children's Oncology Group protocols, 78 (6.7%) were treated according to Dana Farber Cancer Institute protocols and the remainder were others or unknown.

[Table 1](#tbl1){ref-type="table"} shows the demographic, leukaemic and socioeconomic features of the study cohort by enrollment status. Those enrolled were more likely to be white, have an initial WBC\<50 × 10^9 ^l^−1^, CNS 2 status, B precursor immunophenotype and favourable cytogenetic features. [Table 2](#tbl2){ref-type="table"} illustrates the reasons for non-enrollments for centres outside of Ontario and shows that the most common known reason for non-enrollment was lack of an available trial.

Event-free survival at 5 years was 89.8%±0.9 *vs* 84.1%±1.2, *P*\<0.0001, for those enrolled and not enrolled on a therapeutic trial at diagnosis respectively ([Figure 1](#fig1){ref-type="fig"}). Overall survival at 5 years was 94.1%±0.7 *vs* 90.5%±1.0, *P*=0.001 ([Figure 2](#fig2){ref-type="fig"}). [Table 3](#tbl3){ref-type="table"} shows univariate Cox proportional hazards models evaluating factors associated with survival. Enrollment on trials was significantly associated with better EFS (HR: 0.62, 95% CI: 0.49--0.78; *P*\< 0.0001) and OS (HR: 0.61, 95% CI: 0.45--0.82; *P*=0.001). When stratified by NCI risk status and presented by those enrolled *vs* not enrolled, EFS was 91.0±1.0 *vs* 86.8±1.3 (*P*=0.006) for standard-risk patients and was 86.9±1.8 *vs* 78.7±2.3 (*P*=0.006) for high-risk patients, respectively. Overall survival was 96.2±0.7 *vs* 93.4±1.0 (*P*=0.014) for standard-risk patients and was 88.5±1.9 *vs* 84.1±2.3 (*P*=0.093) for high-risk patients.

[Table 4](#tbl4){ref-type="table"} illustrates adjusted analyses by demographic, leukaemic and socioeconomic factors and adjustment for all factors together. In the fully adjusted model, enrollment on trials was significantly associated with better EFS (HR: 0.67, 95% CI: 0.47--0.95; *P*=0.023) but not OS (HR: 0.69, 95% CI: 0.44--1.08; *P*=0.102). To determine if the impact of enrollment on EFS differed by age group, an interaction term was evaluated in a multivariable model which included enrollment and age. The *P*-value for interaction was 0.870 suggesting a similar effect across age groups.

When examining the proportion of treatment plans terminated early rather than completed as planned, 249 out of 1408 (17.7%) for those enrolled were terminated early compared to 156 out of 1161 (13.4%) for those not enrolled (*P*=0.004). When the analysis was restricted to children with ALL treated according to Children's Oncology Group trials, enrollment was associated with better EFS (HR: 0.61, 95% CI: 0.42--0.88; *P*=0.008) and OS (HR: 0.46, 95% CI: 0.27--0.76; *P*=0.003). This benefit was not seen when the analysis was restricted to children treated according to Dana Farber Cancer Institute trials; enrollment was not associated with better EFS (HR: 0.75, 95% CI: 0.35--1.63; *P*=0.475) or OS (HR: 1.11, 95% CI: 0.39--3.21; *P*=0.843).

Discussion
==========

We found that enrollment on a therapeutic clinical trial at initial leukaemic diagnosis was independently associated with better EFS for children newly diagnosed with ALL after adjustment for demographic, leukaemic and socioeconomic factors. Improved EFS was also seen when stratified by NCI risk status. This information may be important to families and clinicians when deciding whether to enroll on a clinical trial at diagnosis.

Our results are discordant with ([@bib5]) who evaluated the trial effect among paediatric ALL patients treated at Seattle Children's Hospital from 1997 to 2005. They failed to demonstrate an EFS advantage to participation in studies However, this report was limited since it included only a single centre in the United States. Further, the sample size consisted of only 322 patients (with 48.8% enrolment).

Reasons why enrollment on trials could improve EFS include the following: (1) Treatment effect, in which the interventions being evaluated result in better outcomes compared with standard approaches; (2) Participation effect where enrollment in the trial results in better outcomes due to the effect of the protocol, changes in healthcare professional behavior, changes in patient/family behavior or a placebo effect; and (3) Confounding, if patients enrolled on trials are systematically different than patients not enrolled on trials. The adjusted analyses were important as those enrolled on trials, when compared to those not enrolled, had generally favourable features such as low initial WBC, B precursor immunophenotype and favourable risk cytogenetics. By taking into consideration confounding using several approaches, our study suggests that improved EFS may be the result of the interventions being evaluated in these studies and is consistent with improved outcomes in paediatric ALL with successive clinical trials ([@bib8]). However, we cannot exclude that participation effect may have a role as well. If improved EFS is the result of interventions being evaluated, this finding may not apply to trials examining de-escalation of therapy.

We also found that when patients were treated with COG protocols, patients enrolled had better outcomes compared to those not enrolled, whereas a similar pattern was not seen among those treated according to Dana Farber Cancer Institute protocols. This finding may be related to either the interventions being evaluated in specific trials or may be related to the smaller number of children receiving Dana Farber Cancer Institute studies. We also found that those enrolled on trials were more likely to terminate the treatment plan early compared to those not enrolled on trials. This finding may be an artefact of how the data were collected since if patients enrolled on trials were taken off protocol therapy but continued to follow the same treatment protocol, they were designated as terminating treatment early and starting a new treatment plan as a non-registered patient.

Our results were less definitive regarding whether enrollment on trials improves OS and such an effect is difficult to demonstrate in a disease with high success rates in general. While we found that OS was not improved in the adjusted models, it should be noted that the HR favoured enrollment and that power was limited given excellent survival. Thus, combining the CYP-C data set with other population-based registries may help us understand whether enrollment on trials can reduce mortality.

The strengths of this study are its population-based nature and careful collection of confounders, including leukaemic and socioeconomic factors. Other strengths are the high quality of data and common health care system, which provides universal healthcare. However, these results must be interpreted in light of its limitations. First, potentially important covariates were not available such as minimal residual disease (MRD) status. Second, we did not include adolescent and young adult patients (AYA) in our study. This is important as several studies have identified that AYA patients have lower rates of enrollment on clinical trials ([@bib2]; [@bib4]; [@bib1]). Third, we lacked immunophenotype information for over 40% of children related to how POGO classifies ALL; this missing data affected the power of analyses, which adjusted for leukaemic-related factors. Finally, we used a census based measure of family income as individually reported data from the family were not available at the population level.

In conclusion, EFS was significantly better in children with ALL enrolled on a clinical trial. Future research should identify barriers to clinical trial enrollment for children with ALL.
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###### Demographics of acute lymphoblastic leukaemia study population by enrollment status

  **Characteristics**                                                **Total** ***N*****=2569**   **Enrolled (*****N*****=1408)**   **Not enrolled (*****N*****=1161)**  **Percent enrolled**   ***P*****-value**[a](#t1-fn1){ref-type="fn"}
  ----------------------------------------------------------------- ---------------------------- --------------------------------- ------------------------------------- ---------------------- ----------------------------------------------
  **Demographic features**                                                                                                                                                                      
  Age at diagnosis                                                                                                                                                                              0.501
   1--4 years                                                               1411 (54.9%)                    788 (56.0%)                         623 (53.7%)              55.8                    
   5--9 years                                                               732 (28.5%)                     393 (27.9%)                         339 (29.2%)              53.7                    
   10--14 years                                                             426 (16.6%)                     227 (16.1%)                         199 (17.1%)              53.3                    
  Male sex                                                                  1451 (56.5%)                    810 (57.5%)                         641 (55.2%)              55.8                   0.238
  Race                                                                                                                                                                                          \<0.0001
   White                                                                    1752 (68.2%)                   1051 (74.6%)                         701 (60.4%)              60.0                    
   Asian                                                                    306 (11.9%)                     132 (9.4%)                          174 (15.0%)              43.1                    
   Arab/West Asian                                                           48 (1.9%)                       24 (1.7%)                           24 (2.1%)               50.0                    
   Aboriginal                                                                73 (2.8%)                       39 (2.8%)                           34 (2.9%)               53.4                    
   Black                                                                     54 (2.1%)                       28 (2.0%)                           26 (2.2%)               51.9                    
   Latin American                                                            37 (1.4%)                       17 (1.2%)                           20 (1.7%)               45.9                    
   Other                                                                     52 (2.0%)                       25 (1.8%)                           27 (2.3%)               48.1                    
   Unknown                                                                   247 (9.6%)                      92 (6.5%)                          155 (13.4%)              37.2                    
  Diagnostic era                                                                                                                                                                                 
   \<2007                                                                   1280 (49.8%)                    712 (50.6%)                         568 (48.9%)              55.6                   0.429
   ⩾2007                                                                    1289 (50.2%)                    696 (49.4%)                         593 (51.1%)              54.0                    
  **Leukaemia features**                                                                                                                                                                        
  Initial white blood cell count                                                                                                                                                                 
   \<50 × 10^9^ l^-1^                                                       2115 (82.3%)                   1190 (84.5%)                         925 (79.7%)              56.3                   0.002
   ⩾50 × 10^9^ l^-1^                                                        454 (17.7%)                     218 (15.5%)                         236 (20.3%)              48.0                    
  CNS status                                                                                                                                                                                     
   CNS1                                                                     2292 (89.2%)                   1237 (87.9%)                        1055 (90.9%)              54.0                   0.002
   CNS2                                                                      217 (8.4%)                     142 (10.1%)                          75 (6.5%)               65.4                    
   CNS3                                                                      53 (2.1%)                       28 (2.0%)                           25 (2.2%)               52.8                    
   Unknown                                                                    7 (0.3%)                       1 (0.1%)                            6 (0.5%)                14.3                    
  Immunophenotype                                                                                                                                                                               0.0006
   B-precursor                                                              1313 (51.1%)                    810 (57.5%)                         503 (43.3%)              61.7                    
   T                                                                         159 (6.2%)                      75 (5.3%)                           84 (7.2%)               47.2                    
   Unknown                                                                  1097 (42.7%)                    523 (37.1%)                         574 (49.4%)              47.7                    
  Cytogenetic risk group                                                                                                                                                                        0.039
   Favourable                                                               779 (30.3%)                     454 (32.2%)                         325 (28.0%)              58.3                    
   Standard                                                                 1673 (65.1%)                    897 (63.7%)                         776 (66.8%)              53.6                    
   Unfavourable                                                              117 (4.6%)                      57 (4.0%)                           60 (5.2%)               48.7                    
  **Socioeconomic factors**                                                                                                                                                                     
  Median Km to nearest tertiary care centre (interquartile range)        29.3 (12.7--104.5)             30.1 (12.5--106.6)                   28.7 (13.3--99.3)                                  0.689
  Income quintile                                                                                                                                                                               0.485
   1 (lowest)                                                               486 (18.9%)                     254 (18.0%)                         232 (20.0%)              52.3                    
   2                                                                        479 (18.6%)                     259 (18.4%)                         220 (18.9%)              54.1                    
   3                                                                        517 (20.1%)                     298 (21.2%)                         219 (18.9%)              57.6                    
   4                                                                        537 (20.9%)                     292 (20.7%)                         245 (21.1%)              54.4                    
   5 (highest)                                                              502 (19.5%)                     282 (20.0%)                         220 (18.9%)              56.2                    
   Missing                                                                       48                             23                                  25                                           

*P*-value by Chi square test for categorical variables and by Wilcoxon rank sum test for continuous variable.

###### Reasons for non-enrollment on trials in 12 non-Ontario institutions

                                                           **Total (*****N*****=595)**
  ------------------------------------------------------- -----------------------------
  No available trial[a](#t2-fn1){ref-type="fn"}                    319 (53.6%)
  Language barrier, trial not offered                               9 (1.5%)
  Not eligible for any trial[a](#t2-fn1){ref-type="fn"}             54 (9.1%)
  Physician choice                                                  24 (4.0%)
  Refused therapy                                                   5 (0.8%)
  Refused to participate in trial                                  62 (10.4%)
  Other                                                             14 (2.4%)
  Unknown                                                          108 (18.2%)

No available trial suggests that a trial was not available for a specific disease. In contrast, not eligible for any trial suggests that a trial was available for a patient's disease but the patient did not meet that trial's eligibility criteria.

###### Impact of trial enrollment on event-free and overall survival[a](#t3-fn2){ref-type="fn"}

                                    **Event-free survival**  **Overall survival**                       
  -------------------------------- ------------------------- ---------------------- ------------------- ----------
  **Enrollment on trial**                                                                               
  Enrolled                             0.62 (0.49--0.78)     \<0.0001                0.61 (0.45--0.82)  0.001
  **Demographic features**                                                                              
  Age at diagnosis                                           \<0.0001                                   \<0.0001
   1--4 years                                 REF                                           REF          
   5--9 years                          1.61 (1.24--2.09)     0.0004                  1.82 (1.28--2.58)  0.0009
   10--14 years                        1.92 (1.43--2.58)     \<0.0001                2.54 (1.74--3.70)  \<0.0001
  Sex                                                                                                    
   Male                                1.32 (1.05--1.68)     0.020                   1.41 (1.03--1.93)  0.031
  Race                                                       0.213                                      0.131
   White                                      REF                                           REF          
   Asian                               0.73 (0.50--1.09)     0.124                   0.73 (0.43--1.22)  0.227
   Arab/West Asian                     1.17 (0.55--2.48)     0.690                   0.57 (0.14--2.29)  0.426
   Aboriginal                          1.55 (0.89--2.71)     0.125                   1.92 (0.97--3.77)  0.060
   Black                               1.04 (0.49--2.21)     0.919                   0.50 (0.12--2.03)  0.502
   Latin American                      0.22 (0.03--1.53)     0.125                   0.40 (0.06--2.83)  0.356
   Other                               0.45 (0.14--1.39)     0.164                   0.51 (0.13--2.08)  0.350
   Unknown                             0.94 (0.61--1.46)     0.795                   1.44 (0.88--2.33)  0.144
  Diagnostic era                                                                                         
   Prior to 2007                       1.87 (1.46--2.40)     \<0.0001                1.72 (1.24--2.37)  0.001
  **Leukaemia features**                                                                                
  Initial white blood cell count                                                                         
   ⩾50x10^9^ l^-1^                     1.88 (1.45--2.45)     \<0.0001                2.81 (2.04--3.86)  \<0.0001
  CNS status                                                 0.029                                      0.0009
   CNS 1                                      REF                                                        
   CNS 2                               1.20 (0.81--1.79)     0.360                   1.58 (0.98--2.55)  0.063
   CNS 3                               1.46 (0.69--3.09)     0.325                   1.47 (0.54--3.97)  0.449
  Immunophenotype                                                                                        
   B-precursor                         0.47 (0.32--0.70)     0.0002                  0.33 (0.21--0.52)  \<0.0001
  Cytogenetic risk group                                     \<0.0001                                   \<0.0001
   Favourable                          0.36 (0.25--0.50)     \<0.0001                0.27 (0.16--0.45)  \<0.0001
   Standard                                   REF                                           REF          
   Unfavourable                        2.61 (1.83--3.71)     \<0.0001                3.46 (2.29--5.21)  \<0.0001
  **Socioeconomic factors**                                                                             
  Nearest tertiary care centre                                                                           
   Kilometers                          1.00 (1.00--1.00)     0.824                   1.00 (1.00--1.00)  0.183
  Income quintile                                            0.636                                      0.555
   1 (lowest)                                 REF                                           REF          
   2                                   0.86 (0.60--1.23)     0.412                   1.16 (0.73--1.83)  0.530
   3                                   0.92 (0.65--1.31)     0.648                   0.89 (0.55--1.43)  0.620
   4                                   0.77 (0.53--1.10)     0.147                   0.89 (0.55--1.42)  0.617
   5 (highest)                         0.82 (0.57--1.17)     0.277                   0.78 (0.47--1.28)  0.327

Abbreviations: CI=confidence interval; CNS=central nervous system; HR=hazard ratio; REF=reference.

Univariate Cox proportional hazards model in which a HR\<1 indicates better survival.

###### Impact of enrollment on trials on event-free and overall survival in adjusted models[a](#t4-fn2){ref-type="fn"}

                                                                       **Event-free survival**  **Overall survival**                       
  ------------------------------------------------------------------- ------------------------- ---------------------- ------------------- -------
  **Variables included in multiple regression**                                                                                            
  Demographic: age, gender, ethnicity, era                                0.60 (0.48--0.76)     \<0.0001                0.61 (0.45--0.82)  0.001
  Leukaemia: white count, CNS status, immunophenotype, cytogenetics       0.72 (0.53--0.99)     0.040                   0.75 (0.50--1.13)  0.163
  Socioeconomic: distance and income quintile                             0.64 (0.50--0.82)     0.0003                  0.63 (0.45--0.86)  0.004
  Demographic, leukaemic and socioeconomic factors                        0.67 (0.47--0.95)     0.023                   0.69 (0.44--1.08)  0.102

Abbreviations: CI=confidence interval; CNS=central nervous system; HR=hazard ratio.

Multiple Cox proportional hazards model in which the estimates reflect the adjusted effect of enrollment on trials where a HR\<1 indicates better survival.

[^1]: Co-first authors.
